HER2-Mutant Non–small lung cancer (NSCLC): Closing the Gap Between Detection and Optimal Treatment

HER2-Mutant Non–small lung cancer (NSCLC): Closing the Gap Between Detection and Optimal Treatment is organized by i3 Health.

Dates Available:
February 9, 2026 - February 8, 2027

Statement of Need:
Non–small lung cancer (NSCLC) is a biologically diverse type of lung cancer driven by a wide array of molecular alterations. Human epidermal growth factor receptor 2 (HER2) alterations occur in approximately 4% of patients with NSCLC and include gene mutations, gene amplifications, and protein overexpression. HER2-targeted therapies, including antibody-drug conjugates and tyrosine kinase inhibitors, have shown promising efficacy for patients with limited treatment options. Testing for HER2 alterations is crucial in order to identify patients who may benefit from targeted therapies, and interprofessional collaboration is critical to optimizing timely diagnosis and personalized management throughout the care continuum (Ismail et al, 2025). In this activity, Maria E. Arcila, MD, Attending Physician and Deputy Chief of the Molecular Diagnostics Service in the Department of Pathology and Laboratory Medicine at Memorial Sloan Kettering Cancer Center, and Helena A. Yu, MD, Attending Physician and Thoracic Medical Oncologist at Memorial Sloan Kettering Cancer Center, will explore strategies for closing the gap between detection and optimal treatment in NSCLC with HER2 alterations.

Learning Objectives:
Upon completion of this activity, participants should be able to:

• Describe the epidemiology, clinical implications, and diagnostic challenges of HER2-mutant NSCLC
• Interpret NGS reports to identify HER2 mutations and integrate this data into treatment planning
• Evaluate current and emerging treatment options for HER2-mutant NSCLC 
• Apply interprofessional strategies to enhance timely diagnosis, testing, and communication across the care continuum for patients with HER2-mutant NSCLC